Prot #DS7300-189: A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), A B7H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Ext

Project: Research project

Project Details

StatusActive
Effective start/end date10/25/2410/25/27

Funding

  • Quintiles, Inc. (Prot #DS7300-189 // Prot #DS7300-189)
  • Daiichi Sankyo, Inc. (Prot #DS7300-189 // Prot #DS7300-189)